Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone862-261-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.79 billion
Profitability
Miscellaneous
Employees16,900
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan declared a quarterly dividend on Friday, July 19th. Shareholders of record on Tuesday, August 13th will be paid a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 annualized dividend and a yield of 1.86%. The ex-dividend date is Monday, August 12th. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan declared that its board has initiated a share buyback plan on Tuesday, January 29th 2019, which authorizes the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 4.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) posted its earnings results on Tuesday, August, 6th. The company reported $4.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.34 by $0.04. The business had revenue of $4.09 billion for the quarter, compared to analyst estimates of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The business's quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.42 earnings per share. View Allergan's Earnings History.
When is Allergan's next earnings date?
What guidance has Allergan issued on next quarter's earnings?
Allergan updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.
What price target have analysts set for AGN?
22 brokers have issued twelve-month price objectives for Allergan's shares. Their predictions range from $144.95 to $255.00. On average, they anticipate Allergan's stock price to reach $179.43 in the next year. This suggests a possible upside of 12.8% from the stock's current price. View Analyst Price Targets for Allergan.
What is the consensus analysts' recommendation for Allergan?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, Allergan faces loss of exclusivity for many key products. While generic versions of Alzheimer’s treatment, Namenda XR and Estrace cream have been launched, that of blockbuster dry-eye drug, Restasis, is expected to be launched soon. Sales of these products are expected to decline significantly with the introduction of generics. Also, new competition for key growth drivers, Botox, Restasis and Linzess, is a concern. Particularly, the entry of CGRP antibodies in 2018 may have a negative impact on sales of Botox Therapeutics, mainly for the chronic migraine indication. Allergan’s shares have underperformed the industry in the past three months." (1/3/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate AGN Neutral and have a 12-month price target of $180. We think that Allergan is one the highest-quality and most-innovative companies in the Pharma industry. That said, we don’t see a lot of upside to consensus expectations in the near term, which is why we are on the sidelines for now. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $180." (9/14/2018)
Has Allergan been receiving favorable news coverage?
Press coverage about AGN stock has trended positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Allergan.
Are investors shorting Allergan?
Allergan saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 5,926,900 shares, an increase of 16.5% from the June 30th total of 5,088,800 shares. Based on an average daily trading volume, of 4,790,000 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.8% of the company's shares are short sold. View Allergan's Current Options Chain.
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), Eli Lilly And Co (LLY), GlaxoSmithKline (GSK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Zoetis (ZTS), Shire (SHPG) and Vertex Pharmaceuticals (VRTX).
What other stocks do shareholders of Allergan own?
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
- Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)
Who are Allergan's major shareholders?
Allergan's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.36%), BlackRock Inc. (6.04%), Longview Partners Guernsey LTD (2.13%), Northern Trust Corp (1.21%), Baupost Group LLC MA (1.12%) and Invesco Ltd. (0.98%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.
Which institutional investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, King Street Capital Management L.P., Iridian Asset Management LLC CT, Baupost Group LLC MA, BlackRock Inc., Invesco Ltd. and Jennison Associates LLC. View Insider Buying and Selling for Allergan.
Which institutional investors are buying Allergan stock?
AGN stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Magnetar Financial LLC, OZ Management LP, Paulson & CO. Inc., Longview Partners Guernsey LTD, Alpine Associates Management Inc., TIG Advisors LLC and Renaissance Technologies LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $159.11.
How big of a company is Allergan?
Allergan has a market capitalization of $52.19 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.
What is Allergan's official website?
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (NYSE AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
